Position in AKTS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$208,185
New position
Shares Held
11,637
first reported quarter
Ownership
0.021%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026MetLife Investment Management, LLC holds $374,315,342 across 207 Biotechnology names. AKTS ranks #149 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
70,804 | $31,616,818 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
80,930 | $26,074,836 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
152,645 | $25,800,057 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
374,931 | $24,231,790 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
23,567 | $18,208,806 | |
| 6 | FTRE |
Fortrea Holdings Inc.
|
1,805,184 | $17,004,833 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
1,738,062 | $15,659,938 | |
| 8 | VRDN |
Viridian Therapeutics, Inc.\DE
|
708,527 | $13,858,788 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $208,185 | 11,637 | Shares | Defined | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||